JNJ - Aurinia Pharma may be worth $45-$53/share in a potential sale - analyst

Aurinia Pharmaceuticals (NASDAQ:AUPH) may be worth $45-$53/share in a possible sale and may see interest from other pharma cos. besides Bristol Myers, according to Cantor Fitgzerald. Aurinia rose 1.5%. Other companies that could be interested include Amgen (NASDAQ:AMGN), AbbVie (NYSE:ABBV), Johnson & Johnson (NYSE:JNJ) and Otsuka (OTCPK:OTSKF), according to Cantor analyst Alethia Young. A potential deal with Bristol Myers, as reported by Bloomberg last week, would make sense given AUPH's clinicals and development profile. "We believe that all of these companies have commercial franchises that could easily tuck LUPKYNIS into their marketed portfolios," Young, who has an overweight rating on AUPH and and a $34 price target, wrote in a note. The Cantor note follows speculation from Betaville yesterday that GlaxoSmithKline (NYSE:GSK), Roche (OTCQX:RHHBY) and Otsuka (OTCPK:OTSKF) may be reviewing a potential bid for Aurinia with bids ranging from $42 to $44.50. A key question for a potential AUPH acquisition is how the acquirer looks

For further details see:

Aurinia Pharma may be worth $45-$53/share in a potential sale - analyst